Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
 Shares Announced by Shareholders Foundation - ESPR - EconoTimes)
SAN DIEGO, Feb. 23, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Michigan on behalf of certain purchasers of shares of Esperion Therapeutics Inc (NASDAQ:ESPR) over alleged Securities Laws Violations by Esperion Therapeutics.
Investors who purchased a significant amount of shares of Esperion Therapeutics Inc (NASDAQ:ESPR) between August 18, 2015 and September 28, 2015, and/or if you purchased any NASDAQ:ESPR shares prior to August 2015 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: March 14, 2016. NASDAQ:ESPR investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff claims that the defendants issued allegedly false and misleading statements and/or failed to disclose adverse information regarding Esperion's business and prospects, including that there was no clear path to approval for ETC-1002, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial ("CVOT") and that completion of a CVOT could be necessary prior to approval of ETC-1002, and that as a result of these allegedly false statements and/or omissions, Esperion common stock traded at artificially inflated prices between August 18, 2015 and September 28, 2015, reaching as high as $82 per share.
On August 17, 2015, Esperion Therapeutics Inc reported material events from an early August 2015 meeting with the U.S. Food and Drug Administration (“FDA”) regarding the next phase of the approval process for ETC-1002. Esperion Therapeutics Inc stated that during the meeting it was informed by the FDA that Esperion Therapeutics Inc would not have to complete a CVOT to gain approval of ETC-1002. Esperion Therapeutics Inc also informed investors that it had a “‘clear regulatory path forward for development and approval of ETC-1002.’"
On September 28, 2015, Esperion Therapeutics Inc provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the FDA.
Those who purchased Esperion Therapeutics Inc (NASDAQ:ESPR) shares have certain options and should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
